Navigation Links
FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
Date:5/13/2008

DELAND, Fla., May 13 /PRNewswire/ -- USHIFU, LLC, the clinical trial management provider for Focus Surgery, Inc. (Indianapolis, IN), is pleased to announce conditional written approval pending minor changes to the protocol from the FDA to begin a pivotal trial for the treatment of recurrent prostate cancer with the Sonablate(R) 500 in men who have failed external beam radiation therapy.

Dr. Herbert Lepor, Chairman of Urology at NYU School of Medicine and medical monitor for the trial said, "It is my pleasure to serve as the medical monitor for the prostate cancer clinical trial program evaluating the safety and effectiveness of the Sonablate(R) 500 HIFU device."

"I have personally reviewed the preliminary data and observed the Sonablate(R) 500 in action and I am impressed with this advanced technology for ablating the prostate. These rigorous clinical trials will help define the appropriate role of the Sonablate(R) 500 device in the treatment of prostate cancer," Lepor added.

This trial will be conducted at various sites across the U.S. and is expected to enroll approximately 202 subjects and 10 clinical centers. This clinical trial is based on results from the feasibility trial completed in October 2007 which enrolled 11 subjects from two clinical research sites within the U.S. Ten of the eleven subjects had failed external beam radiation therapy prior to participating in the clinical trial. The results of this feasibility trial provided a basis for the pivotal study. Additional studies are still needed to satisfy the safety and effectiveness standards, including long term outcomes, set by the FDA for marketing approval.

The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R) 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate(R) 500 for the treatment of prostate canc
'/>"/>

SOURCE USHIFU, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
3. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
4. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
7. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
8. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
9. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
10. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
11. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014  Semler Scientific, Inc. (Nasdaq: ... company that develops patented products that assist healthcare ... today reported financial results for the third quarter ... "In the third quarter of 2014, ... M.D., chief executive officer of Semler.  "We moved ...
(Date:10/31/2014)... 31, 2014  Zebra Imaging, Inc., the world,s ... today a strategic partnership with the Zygote Media ... anatomy and biomedical models for animation and visual ... markets.  Zygote maintains the world,s most comprehensive library ... has pioneered development of high-end solid 3D anatomy ...
(Date:10/31/2014)... SAN FRANCISCO , Oct. 31, 2014 /PRNewswire/ ... innovative therapeutics, today announced a $26.5 million Series ... global investment firm founded by a team of ... sciences.  Other investors participating in the round include ... Venture Fund.  Representatives from Clarus Ventures and Frazier ...
Breaking Medicine Technology:Semler Reports Third Quarter 2014 Financial Results 2Semler Reports Third Quarter 2014 Financial Results 3Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Imago BioSciences Announces $26.5 Million Financing Led by Clarus Ventures 2
... Oct. 6, 2010 Arena Pharmaceuticals, Inc. (Nasdaq: ... lorcaserin presentations at Obesity 2010, the 28th Annual Scientific ... Lorcaserin, which Arena discovered and developed, is intended for ... loss, in patients who are obese (Body Mass Index, ...
... N.J., and SAN ANTONIO, Oct. 6 ... company, and Mission Pharmacal Company, a privately-held ... market announced today their exclusive co-promotion agreement ... to obstetrician,s, gynecologists and other women,s health ...
Cached Medicine Technology:Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010 2Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010 3Arena and Eisai Announce Upcoming Lorcaserin Presentations at Obesity 2010 4Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 2Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 3Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Women's Health Market 4
(Date:10/31/2014)... Nearly one out of four older Americans say that ... or unwanted medical treatment, according to the latest issue ... & Aging Report ( PP&AR ), which goes ... accountable when they fail to honor patients, end-of-life health ... Advanced Illness Care: Issues and Options ," features 12 ...
(Date:10/31/2014)... Denver, Colorado (PRWEB) October 31, 2014 ... reveals that this workout program was developed by Dan ... also become well-known as a fitness professional and life ... stubborn fat and having toned muscles is not impossible ... in based on suspension training. Suspension training promises efficiency ...
(Date:10/31/2014)... drug combination that can trigger the self-destruct process in ... treatments, according to research that will be presented at ... Liverpool next week*. , When healthy cells are no ... in self destruction. But cancer cells swerve away from ... cells grow out of control – causing tumours to ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 In an effort ... patients, Dr. Majid Jamali announced he will soon offer orthodontics ... by the end of November. , To build upon ... Surgery of New York has become known for, Dr. Jamali ... degrees from such top learning institutions as UCLA, Stanford and ...
(Date:10/31/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its new report, ... indoor air quality (IAQ) market is expected to grow to ... (CAGR) of 7% over the next five years. The equipment ... 7.4%. , Since 2012, continuing media attention focused on ... diseases such as bird flu and the increase in chronic ...
Breaking Medicine News(10 mins):Health News:Advance directives can benefit patients, families, and health care system 2Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 2Health News:Oral & Maxillofacial Surgery of New York Adds Orthodontic Patient Services 3Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3
... Encouraging Families to Be Incredibly Active and Healthy, American Egg ... 13 Today, the nation,s egg farmers will delight thousands ... eggs for the 2009 White House Easter Egg Roll. ... together families to hunt for and race Easter Eggs on ...
... used tiny molecules called microRNAs to help turn adult mouse cells back to ... stem cells , they have the capacity to become any cell type in ... ... researchers has for the first time used tiny molecules called microRNAs to help ...
... lung cancer are less likely to receive recommended chemotherapy and ... no signs of lessening. That is the conclusion of a ... CANCER , a peer-reviewed journal of the American Cancer ... provide appropriate treatments for black patients and to educate them ...
... notion that females only receive finite number of eggs ... Researchers in China have demonstrated that female ovaries may ... subsequently producing offspring. , That runs counter to the ... with a finite number of the eggs or oocytes ...
... ValueRays® ergonomic computer accessories provide infrared heat therapy using infrared ... your hand pain diagnosis results in cold computer hands and ... your computer provides warmth and relief. , ... ...
... Discovery advances search for better treatments, experts say, , , ... they,ve spotted a gene variant that may raise the ... may lead to new drug treatments. , The study ... had multiple members with schizophrenia. A functional DNA change ...
Cached Medicine News:Health News:America's Egg Farmers to Participate in Annual White House Easter Egg Roll Today 2Health News:America's Egg Farmers to Participate in Annual White House Easter Egg Roll Today 3Health News:UCSF Team Closer to Creating Safe Embryonic-Like Stem Cells 2Health News:UCSF Team Closer to Creating Safe Embryonic-Like Stem Cells 3Health News:UCSF Team Closer to Creating Safe Embryonic-Like Stem Cells 4Health News:Racial disparities persist in the treatment of lung cancer 2Health News:Stem Cells Spur New Eggs in Ovaries of Adult Mice 2Health News:Stem Cells Spur New Eggs in Ovaries of Adult Mice 3Health News:Arthritis Hand Pain Relief: Infrared Heat Therapy Ergonomic Computer Workstation 2Health News:Gene Variant Tied to Schizophrenia 2
The Skirts and Vests are made with .50mm Pb in the front and .25mm Pb in the back. When worn, the overlap areas in the front of both the skirt and vest provide 1.0mm Pb protection. The velcro fastene...
Designed to fit the body and priced to fit the budget! The Economy Tie apron has a belt that wraps around the body and ties in the front. Don't let the price fool you.... this apron provides the same...
Setting a new standard in protective apparel. The unique, patented Cool-Tech™ mesh-back design fits the natural contour of the body while reducing the amount of weight carried on the shoulders ...
Features four-way apron closure for super adjustability to fit staff of all shapes and sizes. Top left and right shoulder closures allow adjustment of armhole size and chest area of apron for close a...
Medicine Products: